Drug/Small Molecule:
zonisamide

2D structure

Overview

Generic Names: Zonisamida [Spanish]; Zonisamidum [Latin]; zonisamide
Trade Names: Exceglan; Excegram; Excegran; Zonegran
PharmGKB Accession Id: PA451978

Description

Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may be a carbonic anhydrase inhibitor although this is not one of the primary mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate. (source: Drug Bank)

Indication

For use as adjunctive treatment of partial seizures in adults with epilepsy. (source: Drug Bank)

ATC Therapeutic Category

  • N03AX:Other antiepileptics

Pharmacology, Interactions, and Contraindications

Mechanism Of Action

Zonisamide binds to sodium channels, voltage sensitive calcium channels and to a lesser extent carbonic anhydrase. This blocks or suppresses neuronal depolarization and hypersynchronization. (source: Drug Bank)

Pharmacology

Zonisamide is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. The precise mechanism by which zonisamide exerts its antiseizure effect is unknown, although it is believed that the drug blocks sodium channels which leads to the suppression of neuronal hypersynchronization (i.e. convulsions). Likewise zonisamide has also been found not to potentiate syanptic activity by GABA (gamma amino butyric acid). (source: Drug Bank)

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Primarily hepatic through cytochrome P450 isoenzyme 3A4 (CYP3A4). Undergoes acetylation and reduction, forming N-acetyl zonisamide, and the open-ring metabolite 2–sulfamoylacetyl phenol, respectively. (source: Drug Bank)

Protein Binding

40% (at concentrations of 1.0-7.0 µg/mL) (source: Drug Bank)

Absorption

Variable, yet relatively rapid rate of absorption with a time to peak concentration of 2.8-3.9 hours. Food has no effect on the bioavailability of zonisamide. (source: Drug Bank)

Toxicity

Symptoms of overdose include diminished breathing, loss of consciousness, low blood pressure, and slow heartbeat. (source: Drug Bank)

Isomeric SMILES Code:

c1ccc2c(c1)c(no2)CS(=O)(=O)N (source: Drug Bank)

A list of non-curated publications that mention this drug along with other genes is available.

Drug Targets

Gene Description
CACNA1G Uncurated Annotation (source: Drug Bank)
CA1 Uncurated Annotation (source: Drug Bank)
SCN1A Uncurated Annotation (source: Drug Bank)

A list of non-curated publications that mention this drug along with other drugs is available.

Curated Information

The following diseases are in curated knowledge about this drug.

  Disease Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
Epilepsy
  •   
  • PD
  •   
  •   
  • GN
Publications

Non-Curated Information

A list of non-curated publications that mention this drug along with other diseases is available.

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00909
KEGG Compound ID:
C07504
KEGG Drug ID:
D00538
PubChem Compound ID:
5734
PubChem Substance ID:
188654

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Non-Curated Publications

A list of non-curated publications that mention this drug is available.

PharmGKB integrates drug information from different sources: DrugBank, Open Eye Scientific Software.
Add New Alternate Name
Add New ATC Term
Add Cross Reference
Add a metabolite
Add a text annotation
Add a drug target
hint: enter a gene
    Add a drug interaction
    hint: enter a drug
    PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (GM61374).
    ©2001-2010 PharmGKB.